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Abstract 
Background: The prevalence of type 2 diabetes (T2DM) in younger adults is growing. Compared to the late onset 
T2DM, it is well recognized that the disease tends to behave more aggressively in the younger age group with evi-
dence of premature micro and macrovasular diseases and shorter life span. This increased mortality is largely attrib-
uted to cardiovascular complications. In a recent pilot study, young adults with T2DM were found to have significantly 
lower peak diastolic strain rate (PEDSR) on cardiac MRI (CMR), a forerunner of diabetic cardiomyopathy. Liraglutide, 
a glucagon like peptide-1 (GLP-1) analogue, is one of the new classes of glucose lowering therapies licensed to be 
used in management of T2DM. In randomised controlled trials, liraglutide improves glycaemic control by 1–1.5 % 
with an added benefit of weight loss of 2–3 kg. In addition, there is emerging evidence elucidating the cardioprotec-
tive effects of GLP-1 analogues independent of glycaemic control. In a small study, liraglutide has also been shown to 
improve cardiac function in patients with coronary ischaemia or congestive heart failure.
Methods and aims: This is a prospective, randomised, open-label, blind end-point (PROBE) active-comparator trial. 
A total of 90 obese eligible participants with T2DM (18–50 years) will be randomised to either liraglutide 1.8 mg once 
daily or sitagliptin 100 mg once daily for 26 weeks. The primary aim is to assess whether liraglutide improves diastolic 
function compared to sitagliptin as measured by PEDSR using CMR.
Discussion: Although newer classes of GLP-1 analogues are made available in recent years, there are very few 
published studies demonstrating the beneficial effect of GLP-1 analogues on cardiovascular endpoints. In a recently 
published LEADER study, liraglutide has shown superiority to placebo in a population of type 2 diabetes with high 
risk of cardiovascular disease. To the best of our knowledge, there are no published studies establishing the effect of 
liraglutide on cardiac function in younger patients with T2DM on a larger scale. The LYDIA study will comprehensively 
describe changes in various parameters of cardiac structure and function in patients treated with liraglutide aiming to 
provide new evidence on effect of liraglutide on diastolic function in young obese people with T2DM.
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Background
T2DM in young adults and CVD
In the last two decades, the age of onset of type 2 dia-
betes (T2DM) has decreased with a sharp rise in preva-
lence of T2DM under 40  years of age [1, 2]. Emerging 
evidence has shown that increased obesity along with 
increased sedentary life styles have contributed to the 
downward shift in age of onset of this condition. In the 
US, the observed 70 % increase in obesity in young adults 
(18–29 years) remarkably parallels a 70 % rise in T2DM 
in adults under 40 years of age [3]. The typical phenotype 
of obesity, signs of insulin resistance and prevalence of 
cardiovascular risk factors such as hypertension and dys-
lipidaemia are very common in this subset of patients. In 
younger adults, T2DM tends to behave more aggressively 
with an evidence of premature micro and macrovasular 
diseases [4] despite the young age and a relatively short 
duration of diabetes [5].
There is increasing evidence in the literature that devel-
oping T2DM in a younger age is a high risk condition for 
premature atherosclerotic [6] changes and premature 
cardiovascular disease (CVD) [7]. Although the absolute 
risk of CVD was reportedly higher in older adults with or 
without diabetes, younger adults with early-onset T2DM 
have a higher risk compared to age-matched controls. 
The risk of developing a myocardial infarction in young 
adults with T2DM is 14-fold higher than control sub-
jects compared to fourfold higher in those with late onset 
T2DM [8].
Chronic heart failure (CHF) is a major cause of prema-
ture mortality in T2DM. Data from the National Diabe-
tes Audit 2011–12 (NDA), which includes data on almost 
2  million patients with diabetes, has shown that CHF 
was second only to end stage renal disease as a cause of 
death, and diabetic patients with heart failure were four 
times more likely to die prematurely than those without 
[9]. Over one quarter (28 %) of hospitalisations for CHF 
in the UK (716,106) had diabetes, despite a prevalence 
of only 5  % in the general population [10]. The NDA 
concluded that preventing, detecting and treating CHF 
should become a diabetes management priority.
Diastolic dysfunction in T2DM
Although the majority of patients with CHF have 
impaired left ventricular systolic function with reduced 
ejection fraction (EF), there is increasing awareness of 
patients with CHF with a normal EF (HF-NEF), particu-
larly in primary care [11]. Patients with HF-NEF have 
abnormalities of left ventricular relaxation (diastolic dys-
function). There is a high prevalence of diabetes in both 
forms of CHF. Recent data from our centre has found 
almost half of patients with HF-NEF (48/101) had diabe-
tes (unpublished data).
It has long been appreciated that patients with diabe-
tes can have heart failure even in the absence of coro-
nary artery disease, hypertension or valvular heart 
disease, described as diabetic cardiomyopathy [11, 12]. 
According to Maisch’s proposed classification, asympto-
matic diastolic dysfunction with preserved ejection frac-
tion is the earliest stage of diabetic cardiomyopathy [13]. 
In T2DM, the prevalence of left ventricular diastolic 
dysfunction varies between 35 and 60 % [14–16]. Adults 
with diastolic dysfunction are known to be at increased 
risk of progressing to heart failure if there is co-existing 
CVD or other cardiovascular risk factors are not well 
controlled [17].
We and others have shown that adolescents and young 
adults with diabetes already have evidence of diastolic 
dysfunction compared to age matched healthy controls 
[18, 19]. Using cardiac MRI (CMR) our group has shown 
that peak early diastolic strain rate (PEDSR) is approxi-
mately 10 % lower in young adults (18–40) with T2DM 
compared to obese controls, and 20 % lower compared 
to lean controls. There was also a strong trend towards 
reduced systolic strain in T2DM (21  %) compared to 
both control groups (23  % p  =  0.08), suggesting these 
patients may be on the verge of developing systolic as 
well as diastolic impairment. Therefore sub-clinical 
abnormalities in diastolic function are already present in 
young adults with T2DM, despite a relatively short dura-
tion of disease, which may predispose these patients to 
heart failure.
The mechanism causing these abnormalities is unclear 
but in our study duration of diabetes and arterial stiffness 
were both associated with PEDSR [18]. Other proposed 
causes of diastolic dysfunction in T2DM include vascular, 
inflammatory, epigenetic, and neuroendocrine mecha-
nisms, as well as myocardial steatosis. We did not see an 
association of diastolic dysfunction with myocardial per-
fusion reserve or HbA1c. However, other studies suggest 
a relationship between glycaemic control and diastolic 
dysfunction [20, 21]. Therefore, therapeutic strategies 
that simultaneously target both glycaemic control and 
diastolic cardiac function will be desirable in younger 
adults with T2DM.
GLP therapies and CV function
Based on enhancing the effect of naturally occurring gut 
hormone Glucagon like peptiede-1 (GLP-1), novel thera-
peutic agents have been developed and made available 
in the management of T2DM in the last decade. GLP-1 
is secreted from the small intestine in response to oral 
glucose ingestion and is a potent stimulator of insulin 
secretion [22]. Physiologically, the action of GLP-1 is 
short-lived due to rapid inactivation by the dipeptidyl 
peptidase-4 (DPP-4) enzyme inhibitor.
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Incretin based therapies either mimic GLP-1 action 
because they are structurally similar to GLP-1 (GLP-1 
analogues) or they act to reduce the breakdown of GLP-1 
by the inhibition of DPP-4 (DPP-4 inhibitors) [23]. In 
addition to their comparable glucose lowering effects 
to existing therapies, these new agents offer the advan-
tage of having a low risk of hypoglycaemia and either 
weight loss (GLP-1 analogue) or weight neutrality (DPP-4 
inhibitor).
Emerging experimental evidence suggest that GLP-1 
therapy has specific cardioprotective effects independ-
ent of weight loss or improvement in glycaemic control. 
The cardio-protective effects are postulated to be medi-
ated via both the GLP-1 receptor (GLP-1R) dependent 
and independent pathways involving nitric oxide medi-
ated vasodilatory pathways, reduction of inflammatory 
mediators such as hs-CRP, monocytes and macrophages 
etc. [24, 25] .
In particular, GLP-1 treatment has been shown to 
have direct effects on cardiac function and structure. 
In small scale animal and human studies, infusion of 
GLP-1 analogue improves coronary blood flow and left 
ventricle (LV) function in those with chronic heart fail-
ure or after CABG and angioplasty following myocardial 
ischaemia [26–28]. In rat and canine models of heart 
failure/cardiomyopathy have demonstrated that GLP-1 
administration is associated with improved cardiac out-
put, decreased LV end-diastolic volume and reduced 
myocyte apoptosis [29]. Furthermore, mice lacking the 
GLP-1 receptor were reported to have LV diastolic dys-
function, greater LV wall thickening and impaired LV 
contractile function [30].
However, human studies confirming this link between 
GLP-1 treatment and cardiac function and structure are 
limited. In a small study of 12 patients with CHF, LV 
function as well as their exercise capacity improved after 
5  weeks treatment with GLP-1 therapy [27]. Similarly, 
72 h of GLP-1 infusion was associated with improved LV 
ejection fraction in survivors of acute myocardial infarc-
tion [26] and GLP-1 analogue (exenatide) administered 
during percutaneous coronary intervention reduced rep-
erfusion injury and infarct size [31]. Although promising, 
these studies are limited by their small sample size and 
the non-randomised methodology. However several ran-
domised trials have recently been published. In one study 
20 patients were randomised to GLP-1 or saline infu-
sion after percutaneous coronary intervention; GLP-1 
was found to ameliorate LV dysfunction [32]. Another 
randomised cross-over study demonstrated that GLP-1 
therapy improved LV function in 14 patients with coro-
nary artery disease [33]. Whilst the above findings are 
highly promising, data are lacking around the efficacy of 
GLP-1 therapy at improving cardiac function in high risk 
populations without overt cardiovascular disease. This 
limitation is particularly relevant to young individuals 
with T2DM who are likely to have extreme levels of obe-
sity and present with sub-clinical diastolic dysfunction. 
Therefore research is needed to investigate to what extent 




The aims of the study are to evaluate the effect of liraglu-
tide on cardiac structure and function in younger adults 
with T2DM compared to sitagliptin and assess the effects 
on glycometabolic control and aerobic fitness. The pri-
mary outcome measure is the PEDSR, measured by CMR 
at baseline and 26  weeks. Other measures of cardiac 
structure and function assessed in the study and second-
ary outcome measures are illustrated in Additional file 1: 
Appendices 1 and 2.
The primary hypothesis is that treatment with liraglu-
tide, GLP-1 analogue, for 26 weeks lead to improvement 
in PEDSR in younger adults with T2DM compared to the 
clinically relevant active comparator sitagliptin, a DPP-4 
inhibitor.
Study design
This is a prospective, randomised, open-label, blind 
end-point (PROBE) active-comparator trial. Individu-
als will be randomised to receive a maintenance dose of 
liraglutide 1.8 mg daily or sitagliptin 100 mg daily. Study 
outcomes will be assessed and analysed by individuals 
blinded to intervention allocation.
Study population
Potential participants will be identified from both pri-
mary and secondary care in Leicestershire using elec-
tronic databases. All patients meeting the inclusion and 
exclusion criteria (Table  1) will be invited for screening 
and those who remain eligible after screening will pro-
ceed to visit 1–6 as outlined in Additional file 1: Appen-
dix 3.
Study visits
The outline of the study visits and measures taken is 
shown in Additional file 1: Appendix 4.
Visit 0—screening visit
The study clinician will check eligibility of the potential 
participants and obtain written informed consent. Fol-
lowing this, a preliminary ‘on the spot’ capillary test for 
HbA1c using a near patient testing kit will be carried out. 
Those participants with on the spot HbA1c of either <6 
or  >11  % will be informed on the day that they are not 
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eligible to continue. However, those with preliminary on 
the spot HbA1c ≥6 and ≤11 % will continue through to 
baseline visit 1, to have their eligibility confirmed with 
venous HbA1c. Eligible participants will proceed for 
baseline measures (visit 1).
Baseline and follow‑up data collection visits
Participants will attend 6 data collection visits in 
total during the study over a period of approximately 
6 months.
Visit 1 (baseline visit)
Baseline data including patients’ demographics, medical 
history and anthropometric measures (weight, height, 
waist and hip measure, percentage body fat, muscle 
mass, fat free mass and visceral rating) will be collected. 
Participants will be asked to complete questionnaires 
about their wellbeing and satisfaction with their diabe-
tes treatment. Blood samples will also be taken to check 
a range of baseline measures including diabetes control, 
lipid profile and measures of inflammation and immune 
function. All females of child bearing potential will have 
pregnancy test and assurance of adequate use of contra-
ception will be obtained.
Visit 2 (baseline MRI visit)
Participants will have a comprehensive stress CMR scan 
performed at visit 2 as outlined below. Information about 
the MRI test will have been given to the participant 
before they join the study. Patients who are unable to 
complete the CMR will remain in the study for secondary 
end points.
Visit 3 (week 0)—randomisation visit
Prior to randomisation, participants will undergo a 
maximum incremental exercise test on a stationary 
bicycle (electromagnetically braked cycle ergometer) 
with expired gas analysis to determine maximal oxygen 
consumption (VO2max), the gold standard assessment 
of cardiovascular fitness. They will then be randomly 
assigned to either liraglutide or sitagliptin (1:1) using an 
independent online computerised randomisation sys-
tem. Up-titration of liraglutide dose will occur at week 
1(0.6 mg), week 2 (1.2 mg) and week 3 (maintenance dose 
of 1.8 mg). Monitoring and adjusting background medi-
cation are discussed in the following section under study 
medication. Follow up telephone contact will be made to 
check participant’s drug tolerance and report any adverse 
events between visit 3 and 4.
Table 1 Inclusion and exclusion criteria
Inclusion criteria
Capacity to provide informed consent before any trial-related activities
Individuals aged 18–50 years inclusive
Established T2DM
BMI ≥30 kg/m2 (≥27 kg/m2 for South Asians or other BME populations)
On mono or combination oral OAD therapy (sulphonylurea and/or metformin) for ≥ 3 months
No prescribed thiazolidinediones within the last 3 months
An HbA1c value of greater than or equal to 6.5 % and less than 10 % (venous blood)
Exclusion criteria
<18 years old
Absolute contraindications to MRI
Type 1 diabetes (identified through C-peptide analysis in cases of diagnostic uncertainty)
Females of child bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using or willing to use adequate contra-
ceptive methods
Suffer from terminal illness
Have impaired renal function (eGFR <30 ml/min/1.73 m2)
Impaired liver function (ALT ≥2.5 times upper limit of normal)
Known Hepatitis B or Hepatitis C
Clinically significant active cardiovascular disease including history of myocardial infarction within the past 6 months and/or heart failure (NYHA class III 
and IV) at the discretion of the investigator
Recurrent major hypoglycaemia as judged by the investigator
Known or suspected allergy to the trial products
Known or suspected thyroid disease (such as thyroid nodule or thyroid cancer)
Receipt of any investigational drug within 4 months prior to this trial
Have severe and enduring mental health problems
Are not primarily responsible for their own care
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Visit 4 (week 12)
First follow up will be conducted at 12 weeks. Measures 
taken during visit 1 will be repeated.
Visit 5–6 (week 26)
The CMR scan and measures taken at visit 1 and 3 will be 
repeated at the final two follow-up visits. Visit 6 will be 
the end of study.
Study medications
Name: Liraglutide (Victoza) or Sitagliptin (Januvia).
Pharmaceutical form: Solution for liraglutide and tablet 
for sitagliptin.
Pharmaceutical dosage and accountability: liraglu-
tide will be self-administered as subcutaneous injection 
initiated at 0.6 mg daily in week 1, titrated up to 1.2 mg 
daily in week 2 and maintenance dose of 1.8 mg thereaf-
ter until completion of the study as advised per the study 
team. Sitagliptin dose will be self-administered orally 
100 mg daily. Dose of both medications will be lowered 
to the maximum tolerated dose at the investigator discre-
tion. Local NHS Trust pharmacies will be supplying the 
sitagliptin whilst Novo Nordisk will be supplying the lira-
glutide, which will be dispensed by the UHL pharmacy.
Background medication and glycaemic control
Use of metformin or sulphonlyurea (SU) will be con-
sidered as background medication (non-investigational 
medicinal product). Participants treated with either met-
formin or SU at inclusion into the study will continue 
their pre-study dose throughout the study. If the HbA1c 
level falls  <7  % (58  mmol/l), SU dose will be halved at 
baseline or stopped during the study if hypoglycaemia 
develops. Other dose reductions in SU therapy due to 
hypoglycaemia will be allowed at the discretion of the 
principle investigator.
Rescue medication
The criterion for starting glycaemic rescue therapy is a 
fasting plasma glucose value of 11.1 mmol/l at 12 weeks. 
Rescue therapy initiated will be determined by the inves-
tigator as clinically appropriate, either up titration of cur-
rent anti-hyperglycaemic agents (AHA) or the stepwise 
addition of non-insulin AHA(s) and then insulin thera-
pies. All patients receiving rescue therapy will be fol-
lowed up until the end of the study.
MRI
The MRI protocol is outlined in Fig.  1 and is similar to 
that previously described [34] but at 1.5 T (Aera, Siemens, 
Erlangen), as the reproducibility of PEDSR appears to be 
better at this field strength than at 3T [35]. In addition 
thoracic and abdominal subcutaneous and visceral fat 
assessment using Dixon gradient-echo pulse sequence will 
be undertaken [36]. After localisers, Dixon sequences will 
be acquired covering the thorax and abdomen. Steady-
state free precession cine images will be acquired in 4-, 3-, 
and 2-chamber views. Myocardial tissue tagging will be 
performed in three short axis slices to assess pre and post 
contrast (15 min) T1 maps will be obtained in a mid-short 
axis slice to determine gadolinium volume of distribution 
correcting for haematocrit [37, 38]. Perfusion images will 
be acquired after pharmacological vasodilation with aden-
osine, 140 μg/kg/min, for 2–3 min and during data acqui-
sition until a haemodynamic response is achieved (a drop 
in blood pressure of 10 mmHg and/or a rise in heart rate 
of 10  bpm). A gadolinium-based contrast agent (Mag-
nevist, Bayer Healthcare, Leverkusen, Germany) will be 
administered intravenously (0.04 mmol/kg) at 5 ml/s, fol-
lowed by a 20 ml saline flush. First-pass perfusion will be 
assessed for three slices (basal, mid, and apical) acquiring 
every heartbeat using a saturation recovery gradient echo 
sequence. Rest imaging will be performed approximately 
10 min after stress imaging with a further 0.04 mmol/kg 
of contrast. In the intervening time, a stack of short-axis 
slices will be obtained using cine imaging covering the 
entire left LV. A further 0.07 mmol/kg of contrast will be 
given to bring the total dose to 0.15  mmol/kg. At least 
10  min after this, late gadolinium enhancement images 
will be obtained with the use of an inversion-recovery 
prepared, segmented gradient echo sequence, as previ-
ously described.
CMR analysis
MRI scans will be anonymised and sent to a standalone 
work station for blinded analysis as previously described 
[18, 35, 39]. Briefly strain and PEDSR will be quantified 
from tagging and cine images using InTag and feature 
tracking respectively. LV volumes, mass and function will 
be calculated using commercially available non-propriety 
software. Interobserver and intraobserver variability will 
be calculated on at least 10 random datasets by two expe-
rienced observers and results reported. The epicardium 
and endocardium will be contoured on the perfusion 
images, along with a region of interest in the LV blood 
pool, to generate signal intensity curves. MPR will be cal-
culated using Fermi-constrained deconvolution as previ-
ously described [18]. Pre and post contrast (15 min) T1 
maps will be obtained in a mid-short axis slice to deter-
mine gadolinium volume of distribution correcting for 
haematocrit [40]. Late gadolinium enhancement will be 
assessed qualitatively as absent or present and quantified 
by a thresholding technique >5 standard deviations above 
remote normal myocardium [39].
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Statistics
Sample size
The primary aim is to detect a difference in peak diastolic 
strain rate 0.2/s with a standard deviation of 0.3/s from 
baseline to completion of the study (26 weeks). This was 
based on recently published study of obese young sub-
jects with T2DM [13]. With power of 80 % and a 2 sided 
significance of 0.05, the sample size analysis requires 36 
participants per group to complete the study. Allowing 
for a 20 % drop-out, we will aim to recruit 45 participants 
per group.
Statistical methods and analysis
Baseline characteristics will be displayed by group as 
mean and standard deviation (or median interquartile 
range for non-normalised data) for continuous variables 
and counts and percentages for categorical. The dis-
tribution of all primary and secondary variables will be 
assessed. Where data are found to be non-normally dis-
tributed, transformations will be applied. The primary 
outcome will be compared by treatment group using 
analysis of covariance (ANCOVA) modelling, adjusted 
for baseline value; the mean difference between the two 
groups and the 95  % confidence interval will be pre-
sented. A similar analysis will be used for all continuous 
secondary outcomes. Categorical outcomes will be com-
pared by group using logistical regression analysis. All 
statistical tests will be 2 sided and p < 0.05 will be consid-
ered statistically significant.
Participants randomised in the study will be ana-
lysed according to intention to treat (ITT) principle. 
Per-protocol analysis will be carried out as a sensitivity 
analysis for only those who are compliant to the treat-
ment. We will also attempt to address bias by comparing 
the characteristics of those with missing outcome data to 
those who have completed follow up.
Ethical issues
The study is conducted in accordance with the principles 
of the 1996 Helsinki Declarations, ICH-GCP guidelines. 
Ethical approval as a CTIMP was granted by NRES com-
mittee West midlands (13/WM/0311).
Trial oversight and governance
The study sponsor is the University of Leicester and is 
managed by the Leicester clinical trial unit (CTU) and 
is overseen by trial steering committee (TSC) com-
prised of independent chair and a group of experts. 
This study is registered on http://www.clinicaltrials.gov 
(NCT02043054) and monitored by the University of 
Leicester.
Safety of the participants will be independently 
monitored by the Data monitoring and Ethics Com-
mittee (DMEC), which will make recommendations to 
the TSC for appropriate action in the interest of the 
participants.
Current status and time scale
Recruitment started in January 2014 and the last patient 
follow up should complete by June 2016. To date, 103 
patients have been screened, of which 77 were eligible to 
participate and 70 have been randomised to the study.
Fig. 1 Cardiac magnetic resonance imaging (CMR) protocol. CMR protocol used (LA left atrium, LV left ventricle, LGE late gadolinium enhancement)
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Discussion
Heart failure is one of the main determinants of long 
term mortality in patients with T2DM, and subtle abnor-
malities in diastolic function have been reported even at 
early stage of the disease [13]. Once CHF is established it 
is associated with a poor prognosis [41]. There is there-
fore a pressing need to identify therapies that may modify 
the disease process in T2DM and prevent longer term 
cardiac complications.
The benefits of lifestyle interventions such as weight 
loss and exercise on glycaemic control have been 
reported in several large prospective trials. Indeed, 
complete reversal of T2DM has been shown following 
bariatric surgery [42, 43]. However there is limited data 
currently on the effects on cardiovascular outcomes. The 
use of a 471  kcal/day low energy diet in patients with 
T2DM has been shown to be associated with improved 
diastolic filling on CMR [44], and another study sug-
gested a benefit in diastolic parameters following 
3 months of aerobic exercise [45]. Both of these studies 
were small, single centre pilots.
Currently, the evidence for an effect of any glucose 
lowering therapy on cardiovascular outcomes is incon-
sistent, and until recently only metformin (from the 
UKPDS trial) had been shown to have any benefit [46]. 
The recent expansion in classes of hypoglycaemic agents 
has led to several clinical trials specifically evaluating the 
efficacy of these drugs for beneficial effects on cardio-
vascular endpoints, which have generally demonstrated 
neutral effects. The trial evaluating cardiovascular out-
comes with sitagliptin (TECOS), saxagliptin assessment 
of vascular outcomes recorded in patients with diabe-
tes mellitus (SAVOR-TIMI 53) and examination of car-
diovascular outcomes: alogliptin (EXAMINE) studies 
all demonstrated neutral effect on major cardiovascular 
events with DPP-4 inhibitors, sitagliptin, saxagliptin and 
alogliptin [47–49]. Similarly, the ELIXA (evaluation of 
cardiovascular outcomes in patients with type 2 diabe-
tes after acute coronary syndrome during treatment with 
lixisenatide) trial, which examined the GLP-1 agonist 
lixisenatide versus placebo in patients with T2DM and a 
history of recent acute coronary syndrome, found a neu-
tral effect of the drug on adverse cardiovascular events 
[50]. Most recently, the LEADER (liraglutide effect and 
action in diabetes: evaluation of cardiovascular outcome 
results—a long term evaluation) trial demonstrated the 
cardiovascular benefit of liraglutide in high-risk cardio-
vascular patients with T2DM [51]. In fact, liraglutide has 
demonstrated superiority to placebo with a 13 % relative 
risk reduction in the first occurrence of cardiovascular 
death, nonfatal MI or nonfatal stroke and 22 % reduction 
in mortality due to cardiovascular causes. This is the very 
first cardiovascular safety trial among incretin-based 
therapies that has demonstrated positive outcome on 
cardiovascular effect. A another group of new thera-
peutic agents, SGLT-2 inhibitors has also demonstrated 
a 38 % relative risk reduction in mortality due to cardio-
vascular causes in the empagliflozin cardiovascular out-
come event trial in type 2 diabetes mellitus patients trial 
(EMPA-REG) [52].
However, there were concerns about the unexpected 
increased risk of hospitalisation from heart failure in the 
cohort treated with DPP-4 inhibitor, saxagliptin in the 
SAVOR-TIMI 53 study. The vildagliptin in ventricular dys-
function diabetes (VIVIDD) trial demonstrated statistically 
significant increase in LV endiastolic volume and a trend 
towards an increase in LV systolic volume associated with 
vildagliptin [53]. The other studies TESCOS and ELIXA 
trials showed neutral effect on hospitalisations for heart 
failure [47, 50]. In the recently published LEADER study, a 
lower risk of hospitalisation from heart failure was shown 
in the liraglutide group although statistically not significant 
[51]. In general, retrospective data has suggested a possi-
ble beneficial effect of GLP-1 agonists on cardiac function 
in T2DM [54]. The exact mechanism of how the incretin 
based therapies affect cardiac function was not clearly 
understood. Although not necessarily a class effect, the 
investigators believed that the LYDIA study was well placed 
at the time to examine changes in cardiac parameters and 
function following treatment with a DPP-4 inhibitor and 
that sitagliptin as the most widely used DPP-4 inhibitor 
would be a suitable comparator. To the best of our knowl-
edge, this will be the first study in the UK to establish the 
impact of liraglutide on cardiac structure and function 
using CMR in younger adults with T2DM. The study aims 
to comprehensively describe changes in various parameters 
of cardiac structure and function in patients treated with 
liraglutide compared to sitagliptin.
There are limitations in this study. As the study is of 
relatively short duration, no long-term data will be avail-
able from the study beyond 6 months. Secondly, the lack 
of placebo may inadvertently over accentuate the improve-
ment seen with liraglutide, if the DPP-4 inhibitors used 
as a comparator indeed depress myocardial performance. 
However, the results will inform us if treatment with lira-
glutide can actually improve diastolic function and if so, to 
what extent in younger adults with T2DM. This will be of 
clinical relevance to decide management strategies to ame-
liorate the progress of early stages of cardiac dysfunction 
in the future, and if positive would provide justification for 
longer term, prospective trials on the potential benefits of 
GLP-1 agonists to prevent heart failure in this population.
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